Today's Low
₹ 340.00
Today's High
₹ 357.95
52 Weeks Low
₹ 125.00
52 Weeks High
₹ 222.45
Lower
₹ 333.35
Upper
₹ 368.40
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2012 | FY 2011 | FY 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 114.1 | 80.4 | 55.8 | 64.9 | 63.0 | 48.6 | 47.3 | 46.7 | 167.3 | 67.5 | 67.1 |
Total Non-Current Assets | 94.2 | 121.5 | 86.1 | 77.8 | 63.1 | 61.9 | 68.4 | 79.5 | 9.6 | 85.5 | 67.4 |
Total Assets | 208.3 | 201.9 | 141.9 | 142.6 | 126.1 | 110.4 | 115.7 | 126.2 | 176.9 | 153.0 | 134.8 |
Total Current Liabilities | 69.3 | 73.3 | 22.0 | 20.1 | 14.9 | 11.7 | 8.0 | 6.9 | 60.5 | 66.2 | 21.2 |
Total Non-Current Liabilities | -1.2 | -0.9 | -0.6 | -0.6 | -1.6 | -2.5 | -1.0 | -0.5 | 0.8 | 0.9 | 38.5 |
Shareholder's Funds | 139.1 | 127.1 | 118.3 | 121.1 | 112.0 | 101.2 | 108.7 | 119.9 | 114.6 | 84.3 | 75.2 |
Total Liabilities | 208.3 | 201.9 | 141.9 | 142.6 | 126.1 | 110.4 | 115.7 | 126.2 | 176.9 | 153.0 | 134.8 |
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.11, which results in a Positive aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 2.54, which results in a Positive aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 2.29, which results in a Positive aspect.
The Industry Price to BV stands at 6.08, vs the Price to BV of 3.34, which results in a Negative aspect.
Particulars | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2012 | FY 2011 | FY 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 114.2 | 68.5 | 53.3 | 82.5 | 51.0 | 28.7 | 21.0 | 19.0 | 108.0 | 146.3 | 142.7 |
Total Expenditure | 103.7 | 63.2 | 53.3 | 76.5 | 45.7 | 29.2 | 25.3 | 20.8 | 95.3 | 124.2 | 119.0 |
Operating Profit(Excl OI) | 13.4 | 8.0 | 4.5 | 11.3 | 8.6 | 0.6 | -1.5 | 1.0 | 13.7 | 22.2 | 24.2 |
Add: Other Income | 2.9 | 2.7 | 4.6 | 5.3 | 3.3 | 1.1 | 2.8 | 2.7 | 1.1 | 0.2 | 0.5 |
Operating Profit | 13.4 | 8.0 | 4.5 | 11.3 | 8.6 | 0.6 | -1.5 | 1.0 | 13.7 | 22.2 | 24.2 |
Less: Interest | 1.3 | 0.9 | 0.9 | 0.7 | 0.4 | 0.2 | 0.1 | 0.1 | 3.0 | 3.5 | 4.5 |
PBDT | 12.1 | 7.1 | 3.6 | 10.6 | 8.2 | 0.4 | -1.6 | 0.9 | 10.7 | 18.7 | 19.6 |
Less: Depreciation Amortization | 2.5 | 2.0 | 2.0 | 2.1 | 2.0 | 9.8 | 10.1 | 1.9 | 4.9 | 5.6 | 6.1 |
PBT & Exceptional Items | 9.6 | 5.1 | 1.6 | 8.6 | 6.1 | -9.3 | -11.6 | -1.0 | 5.8 | 13.1 | 13.6 |
Less: Exceptional Income Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 91.5 | 0.0 | 0.0 |
Profit Before Tax | 9.6 | 5.1 | 1.6 | 8.6 | 6.1 | -9.3 | -11.6 | -1.0 | 97.4 | 13.1 | 13.6 |
Less: Taxation | 3.4 | 1.4 | 0.8 | 4.8 | 1.0 | -0.4 | -0.4 | -0.7 | 21.1 | 2.6 | 2.8 |
Profit After Tax | 6.2 | 3.8 | 0.8 | 3.8 | 5.2 | -8.9 | -11.2 | -0.3 | 76.3 | 10.5 | 10.7 |
Earnings Per Share | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.6 | 0.1 | 0.1 |
The Industry PAT Margin stands at 9.73, vs the PAT Margin of 1.58, which results in a Negative aspect.
The Industry PAT Growth stands at 32.10, vs the PAT Growth of -78.01, which results in a Negative aspect.
The Industry Dividend Yield stands at 0.59, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PE Ratio stands at 43.11, vs the PE Ratio of 38.76, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2012 | FY 2011 | FY 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 12.0 | 9.6 | 5.1 | 1.6 | 8.6 | 6.1 | -9.3 | -11.6 | -0.9 | -9.7 | 13.1 | 13.5 |
Tax Paid | -4.3 | -2.5 | -1.0 | -2.3 | -4.2 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | -3.2 |
Adjustment | 9.8 | 3.9 | 2.8 | -1.2 | 1.9 | 2.0 | 11.5 | 9.2 | 2.1 | 7.1 | 9.1 | 6.7 |
Changes In Working Capital | 12.0 | 9.6 | 5.1 | 1.6 | 8.6 | 6.1 | -9.3 | -11.6 | -0.9 | -9.7 | 13.1 | 13.5 |
Cash Flow after changes in Working Capital | 6.9 | 8.3 | 46.7 | 6.7 | 4.5 | 1.4 | 1.1 | 17.3 | -7.6 | -29.3 | 22.1 | 15.2 |
Cash Flow from Operating Activities | 2.6 | 5.8 | 45.7 | 4.5 | 0.3 | 1.4 | 1.1 | 17.2 | -7.6 | -29.3 | 22.1 | 12.0 |
Cash Flow from Investing Activities | 7.9 | -15.3 | -37.6 | -10.5 | -14.0 | -4.5 | -1.5 | -19.6 | -31.2 | 41.0 | -23.9 | -20.4 |
Cash Flow from Financing Activities | -0.7 | 7.0 | 1.6 | 0.8 | 16.9 | 5.5 | 0.0 | 0.1 | -0.1 | -9.5 | 7.3 | 7.3 |
Net Cash Inflow / Outflow | 9.8 | -2.4 | 9.7 | -5.1 | 3.2 | 2.5 | -0.5 | -2.2 | -38.9 | 2.2 | 5.5 | -1.1 |
Opening Cash & Cash Equivalents | 10.1 | 12.5 | 2.8 | 7.9 | 4.8 | 2.3 | 2.7 | 5.0 | 43.9 | 9.5 | 4.0 | 5.0 |
Closing Cash & Cash Equivalent | 19.8 | 10.1 | 12.5 | 2.8 | 7.9 | 4.8 | 2.3 | 2.7 | 5.0 | 11.7 | 9.5 | 4.0 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of -94.52, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.27, vs the PCF RATIO of 28.11, which results in a Positive aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 317.9 | 412.0 | 365.6 | 454.8 | 299.7 | 307.0 | 334.5 | 366.1 | 344.3 | 235.7 | 196.3 | 199.3 | 203.3 | 180.7 | 101.9 | 116.2 |
Total Income | 347.5 | 416.9 | 371.2 | 465.0 | 306.6 | 309.4 | 344.2 | 369.9 | 357.4 | 237.4 | 206.8 | 214.4 | 207.0 | 184.9 | 105.6 | 131.0 |
Total Expenditure | 295.2 | 325.8 | 303.8 | 392.6 | 259.9 | 267.4 | 300.3 | 315.6 | 336.7 | 199.1 | 187.2 | 196.0 | 173.1 | 151.2 | 113.0 | 139.3 |
PBIDT (Excl OI) | 22.8 | 86.2 | 61.8 | 62.1 | 39.8 | 39.5 | 34.2 | 50.5 | 7.6 | 36.6 | 9.0 | 3.3 | 30.2 | 29.6 | -11.1 | -23.1 |
Other Income | 29.6 | 4.9 | 5.6 | 10.2 | 6.9 | 2.4 | 9.7 | 3.8 | 13.1 | 1.7 | 10.5 | 15.1 | 3.7 | 4.2 | 3.7 | 14.7 |
Operating Profit | 52.4 | 91.1 | 67.4 | 72.3 | 46.7 | 41.9 | 43.9 | 54.3 | 20.7 | 38.3 | 19.6 | 18.4 | 33.9 | 33.8 | -7.4 | -8.3 |
Interest | 16.0 | 15.1 | 15.0 | 12.1 | 12.9 | 17.5 | 6.7 | 7.1 | 2.4 | 1.2 | 1.3 | 1.6 | 1.2 | 1.8 | 2.9 | 2.3 |
Exceptional Items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 36.4 | 76.0 | 52.4 | 60.3 | 33.8 | 24.4 | 37.2 | 47.1 | 18.4 | 37.0 | 18.3 | 16.7 | 32.7 | 32.0 | -10.4 | -10.6 |
Depreciation | 8.2 | 8.2 | 7.9 | 9.1 | 9.3 | 8.9 | 8.2 | 11.3 | 2.0 | 7.0 | 4.4 | 5.0 | 5.0 | 5.0 | 4.9 | 5.2 |
Profit Before Tax | 28.2 | 67.8 | 44.5 | 51.1 | 24.5 | 15.5 | 29.0 | 35.9 | 16.4 | 30.1 | 13.9 | 11.7 | 27.7 | 27.1 | -15.2 | -15.9 |
Tax | 10.8 | 16.9 | 13.9 | 22.1 | 7.4 | -3.8 | 11.6 | 12.9 | 10.3 | 4.2 | 6.7 | 4.6 | 5.8 | 5.0 | -1.9 | -3.4 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 17.4 | 50.9 | 30.6 | 29.0 | 17.1 | 19.4 | 17.4 | 23.0 | 6.1 | 25.8 | 7.2 | 7.1 | 21.8 | 22.1 | -13.3 | -12.5 |
Net Profit | 17.4 | 50.9 | 30.6 | 29.0 | 17.1 | 19.4 | 17.4 | 23.0 | 6.1 | 25.8 | 7.2 | 7.1 | 21.8 | 22.1 | -13.3 | -12.5 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 160.8 | 160.8 | 155.8 | 155.8 | 155.8 | 155.8 | 155.8 | 155.8 | 155.8 | 155.6 | 155.6 | 155.0 | 155.0 | 154.8 | 154.8 | 154.3 |
Reserves | 0.0 | 0.0 | 0.0 | 1,360.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 1.9 | 2.9 | 2.2 | 2.3 | 1.5 | 1.6 | 1.3 | 1.9 | 0.7 | 1.4 | 0.8 | 0.5 | 1.4 | 1.3 | -0.9 | -0.8 |
Operating Profit Margin | 16.5 | 22.1 | 18.4 | 15.9 | 15.6 | 13.7 | 13.1 | 14.8 | 6.0 | 16.2 | 10.0 | 9.2 | 16.7 | 18.7 | -7.3 | -7.2 |
Net Profit Margin | 5.5 | 12.4 | 8.4 | 6.4 | 5.7 | 6.3 | 5.2 | 6.3 | 1.8 | 11.0 | 3.7 | 3.5 | 10.7 | 12.2 | -13.1 | -10.7 |
The Industry Mcap Growth stands at 19.65, vs the Mcap Growth of -58.69, which results in a Negative aspect.
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -35.36, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 383.75 | 402.26 | 357.72 |
R3 | 375.15 | 374.78 | 352.79 |
R2 | 366.55 | 366.36 | 351.14 |
R1 | 357.20 | 356.83 | 349.50 |
Pivot | 348.60 | 348.41 | 348.60 |
S1 | 339.25 | 338.88 | 346.20 |
S2 | 330.65 | 330.46 | 344.56 |
S3 | 321.30 | 320.93 | 342.91 |
S4 | 311.95 | 294.56 | 337.98 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
7.39
Bullish
RSI
34.83
Neutral
ROC
-10.31
Bearish
UltimateOscillator
35.25
Neutral
Williams Indicator
-86.92
Bullish
CCI Indicator
-103.83
Bullish
MACD
-2,652.36
Bearish
Stochastic Indicator
13.79
Neutral
ATR
19.83
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
08-02-2024 | Quarterly Results |
09-11-2023 | Quarterly Results |
11-08-2023 | Quarterly Results |
22-07-2023 | Inter alia, to consider and approve conversion of warrants into the equity shares of the Company to the specified person only. |
29-05-2023 | Audited Results |
14-02-2023 | Quarterly Results |
14-11-2022 | Quarterly Results |
10-08-2022 | Quarterly Results |
26-05-2022 | Audited Results |
14-02-2022 | Quarterly Results |
20-12-2021 | Preferential Issue of shares & Issue Of Warrants |
12-11-2021 | Quarterly Results |
13-08-2021 | Quarterly Results |
22-06-2021 | Audited Results |